Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

This program supports early-stage product development for small molecules, biologics, and combination products for NHLBI mission-related diseases and disorders, with work such as lead compound series identification and prototype testing. Eligible applicants include U.S. higher education institutions, nonprofits, for-profits, governments, tribal organizations, faith-based or community-based organizations, regional organizations, and federal agencies; foreign organizations are not eligible, though foreign components of U.S. organizations are allowed. Awards are grants of up to $400,000 in direct costs per year for up to two years, and NHLBI expects up to 24 new awards across this NOFO and three companion announcements in FY 2026–2028. A non-federal cash match of at least 25% of the federal direct costs is expected, and at least one Accelerator Partner is required. Clinical trials are not allowed.

✳ AI-generated summary — verify against the announcement

• Health
• Technology & Product Development
• Researchers & Scholars
• Biomedical & Disease Research

• ✓ City or township governments
• ✓ County governments
• ✓ For-profit organizations other than small businesses
• ✓ Independent school districts
• ✓ Native American tribal governments (Federally recognized)
• ✓ Native American tribal organizations (other than Federally recognized)
• ✓ Nonprofits with 501(c)(3) status (other than higher education)
• ✓ Nonprofits without 501(c)(3) status (other than higher education)
• ✓ Others
• ✓ Private institutions of higher education
• ✓ Public and State controlled institutions of higher education
• ✓ Public housing authorities / Indian housing authorities
• ✓ Small businesses
• ✓ Special district governments
• ✓ State governments